Antibodies that immunospecifically bind to TRAIL receptors
First Claim
1. An isolated antibody or fragment thereof comprising a first amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of either VHCDR1, VHCDR2, or VHCDR3 of any one of SEQ ID NOS;
42-53; and
(b) the amino acid sequence of either VLCDR1, VLCDR2, or VLCDR3 of any one of SEQ ID NOS;
42-53;
wherein said antibody or fragment thereof immunospecifically binds TR4.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.
-
Citations
77 Claims
-
1. An isolated antibody or fragment thereof comprising a first amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:
-
(a) the amino acid sequence of either VHCDR1, VHCDR2, or VHCDR3 of any one of SEQ ID NOS;
42-53; and
(b) the amino acid sequence of either VLCDR1, VLCDR2, or VLCDR3 of any one of SEQ ID NOS;
42-53;
wherein said antibody or fragment thereof immunospecifically binds TR4. - View Dependent Claims (2, 3, 4)
-
-
5. An isolated antibody or fragment thereof comprising:
-
(a) an amino acid sequence that is at least 90% identical to a VH domain of any one of SEQ ID NOS;
42-53;
(b) an amino acid sequence that is at least 90% identical to a VL domain of any one of SEQ ID NOS;
42-53;
or(c) both (a) and (b);
wherein said antibody or fragment thereof immunospecifically binds TR4. - View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)
-
-
75. The antibody expressed by the cell line of ATCC Deposit PTA-3570.
-
76. The antibody expressed by the cell line of ATCC Deposit PTA-3571.
-
77. The antibody expressed by the cell line of ATCC Deposit PTA-3675.
Specification